Fig. 2.

Variant allele frequency (VAF)-related stratification model in predicting immune checkpoint inhibitors (ICIs) response and prognosis. A–B Kaplan–Meier (K-M) survival curve of progression-free survival (PFS) in Training, Test 1, Test 2 cohorts, and overall survival (OS) in Test 3 cohort. The p-value was calculated using the log-rank test. C–D Multivariate Cox regression analysis of risk score level and clinical characteristics in the Training, Test 1, Test 2, and Test 3 cohorts. E Proportion of durable clinical benefit (DCB) and no durable benefit (NDB) patients in high- and low-score groups. Chi-square test; A p-value < 0.05 was considered statistically significant. F Proportion of complete response (CR)/partial response (PR) and stable disease (SD)/progressive disease (PD) patients in high- and low-score groups. Chi-square test; A p-value < 0.05 was considered statistically significant